Delivering Actionable Innovation
We are continuously building on a legacy of excellence, expertise and achievement in viral vector delivery. Our approach to engineering targeted and stable viral delivery solutions has been proven in the clinic with oncolytic viruses. Now, Vyriad’s team of world leaders in cell-specific targeting, virus therapy, and oncology drug development are delivering targeted viral delivery solutions that make in vivo gene therapies possible.
Leveraging a Targeted Approach
A combination of an innovative approach to engineering targeted vectors and expertise across virus families allows us to develop and de-risk the appropriate delivery platform for targeted genetic therapies.
Partnering for Targeted Therapies
Our novel delivery platforms make in vivo gene therapies possible. Now, we are looking to forge partnerships with in vivo gene therapy and genome editing therapeutic developers to realize that potential with us.
For each program we can work collaboratively to:
